First Wave BioPharma to initiate trial of adrulipase for cystic fibrosis

First Wave BioPharma is set to initiate its Phase II clinical trial of an improved adrulipase formulation in exocrine pancreatic insufficiency in cystic fibrosis patients.

The US Food and Drug Administration (FDA) has reviewed First Wave’s investigational new drug (IND) amendment and is yet to provide any further comments in the 60-day review period after it received a modified protocol.